EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 226 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... November 30, 2023 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... August 16, 2021 Load more HOT NEWS Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... ASCO 2021 news: follow-up treatments pave the way ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? Study Links Non-Diet Soda Consumption with a Higher Risk of Death...
